Skip to main content

Hydrocephalus, Normal Pressure

0
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

NeuroDx Development
2 programs
ShuntCheckN/A1 trial
ShuntCheckN/A1 trial
Active Trials
NCT04309487Unknown20Est. Jan 2025
NCT04011566Unknown50Est. Jan 2025
CereVasc
CereVascMA - Charlestown
2 programs
eShunt ImplantN/A1 trial
eShunt ImplantN/A1 trial
Active Trials
NCT05250505Active Not Recruiting30Est. Apr 2030
NCT05232838Active Not Recruiting50Est. Jun 2030
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Non-invasive measuresN/A1 trial
Active Trials
NCT01115270Completed196Est. Oct 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
CereVasceShunt Implant
CereVasceShunt Implant
NeuroDx DevelopmentShuntCheck
NeuroDx DevelopmentShuntCheck
Angeles TherapeuticsNon-invasive measures

Clinical Trials (5)

Total enrollment: 346 patients across 5 trials

NCT05232838CereVasceShunt Implant

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Start: Apr 2022Est. completion: Jun 203050 patients
N/AActive Not Recruiting
NCT05250505CereVasceShunt Implant

Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Start: Mar 2022Est. completion: Apr 203030 patients
N/AActive Not Recruiting
NCT04309487NeuroDx DevelopmentShuntCheck

Diagnostic Accuracy of ShuntCheck Compared to Radionuclide Shunt: Patency in Patients With Normal Pressure Hydrocephalus

Start: Jan 2020Est. completion: Jan 202520 patients
N/AUnknown
NCT04011566NeuroDx DevelopmentShuntCheck

Assessment of ShuntCheck Performance Characteristics in Asymptomatic Patients With Normal Pressure Hydrocephalus

Start: Jun 2019Est. completion: Jan 202550 patients
N/AUnknown
NCT01115270Angeles TherapeuticsNon-invasive measures

A Study Comparing Shunt Placement Versus Endoscopic Third Ventriculostomy in the Treatment of Hydrocephalus

Start: Feb 2007Est. completion: Oct 2011196 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.